Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (7461E)
October 22 2018 - 4:05AM
UK Regulatory
TIDMHCM
RNS Number : 7461E
Hutchison China Meditech Limited
22 October 2018
Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on October 19,
2018, it granted share options under the Share Option Scheme
conditionally adopted by Chi-Med at its Annual General Meeting in
2015 (the "2015 HCML Share Option Scheme").
Chi-Med granted 43,000 share options under its 2015 HCML Share
Option Scheme to certain employees to subscribe for Ordinary Shares
subject to the acceptance of the grantees. Details of such share
options granted prescribed are as follows:
Date of grant : October 19, 2018
Exercise price of share options : GBP46.10 per Ordinary Share
granted
Number of share options granted : 43,000 (each share option shall
entitle the holder thereof to subscribe
for one Ordinary Share)
Closing market price of Ordinary : GBP46.10 per Ordinary Share
Shares on the date of grant
Validity period of the share : From October 19, 2018 to October
options 18, 2028
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development +852 2121 8200
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 1367 179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
POSPGGUUUUPRUBP
(END) Dow Jones Newswires
October 22, 2018 05:05 ET (09:05 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024